RamSoft gets mammo clearance

AuntMinnie.com staff writers

Oct 5, 2005

Canadian PACS vendor RamSoft has received Food and Drug Administration 510(k) clearance for use of its PowerServer 4.0 software suite in digital mammography applications.

The software must be used with 510(k)-cleared displays, RamSoft said. The software upgrade will be available at no cost for customers who have a RamSoft software subscription, according to the Toronto-based vendor.

By AuntMinnie.com staff writers
October 6, 2005

Related Reading

RamSoft adds new PowerServer version, September 29, 2005

RamSoft releases TeleServer, June 17, 2005

Cogent to become RamSoft USA, November 28, 2004

Road to RSNA, RamSoft, November 16, 2004

RamSoft inks PresGar deal, July 28, 2004

Copyright © 2005 AuntMinnie.com

Mammo Adobe Gorodenkoff

Neighborhood deprivation tied to lower breast cancer screening

September 2, 2026

Mammotome expands production of breast biopsy system

September 1, 2026

CureMetrix secures FDA clearance for cmAngio 2.0

August 17, 2026

Longitudinal DBT could help improve long-term cancer risk prediction

August 13, 2026

Neighborhood deprivation tied to lower breast cancer screening

By Amerigo Allegretto

Women residing in neighborhoods with high deprivation have lower odds of getting their mammograms.

September 2, 2026

Mammo Adobe Gorodenkoff

Mammotome expands production of breast biopsy system

By AuntMinnie.com staff writers

The company said it's increasing production to help address a U.S. shortage of stereotactic breast biopsy needles.

September 1, 2026

CureMetrix secures FDA clearance for cmAngio 2.0

By AuntMinnie.com staff writers

The update introduces BAC quantification, age-based BAC percentile scoring compared against a reference library of more than 170,000 studies.

August 17, 2026

Longitudinal DBT could help improve long-term cancer risk prediction

By Amerigo Allegretto

A longitudinal DBT model outperformed other models based on mammography and clinical factors in predicting five-year cancer risk.

August 13, 2026

AI tools may not meet breast radiologists' expectations in practice

By Amerigo Allegretto

AI tools in breast imaging may have more modest clinical impact on recall and biopsy rates.

August 12, 2026

Breast Mammo Computer 400 (3)

NME breast lesions have high malignancy rate on MRI-guided biopsy

By Amerigo Allegretto

Biopsies from women with a known ipsilateral malignancy have a higher frequency of breast cancer.

August 10, 2026

DBT-based foundational model classifies breast density

By Amerigo Allegretto

DBT-DINO showed strong performance in classifying breast density from DBT images.

August 4, 2026

(A) Free-response receiver operating characteristic (FROC) curve for DBT-DINO and DINOv2 (Meta AI) on the detection task. DINOv2 achieved higher sensitivity than DBT-DINO across most false-positive thresholds. (B) Detection rates of DBT-DINO and DINOv2 for lesions that were ultimately found to be benign (n = 70) and lesions that were found to be cancerous (n = 66). Error bars represent 95% CIs estimated via patient-level bootstrapping with 1000 repetitions. Both models showed similar detection rates for cancerous lesions, whereas DINOv2 detected more benign lesions than DBT-DINO. (C) Example bounding box predictions for DBT-DINO and DINOv2 on the detection test set. Each image is a single two-dimensional section from a three-dimensional digital breast tomosynthesis volume; the first column shows a mediolateral oblique view, and the second and third columns show craniocaudal views. Both models struggled to detect very small lesions, such as the 3-mm-diameter lesion shown in the first column. FP = false positive.

RadSite publishes clinical coverage guideline for breast CBCT imaging

By AuntMinnie.com staff writers

The guide outlines how breast CBCT should be used when conventional imaging approaches are inconclusive or inaccessible.

July 30, 2026

CEM finds breast cancer at baseline, incidence screening

By Amerigo Allegretto

Incidence screening with CEM maintains high performance and may offer more benefits over baseline CEM screening.

July 28, 2026

Images in a 70-year-old asymptomatic woman with a prior excisional biopsy in the left breast yielding lobular carcinoma in situ 3 years earlier. Screening contrast-enhanced mammography (CEM) was performed, which was considered a prevalence screen as the woman had no prior breast MRI in the past 3 years and no prior CEM. (A) Low-energy (26–30 kVp) mediolateral oblique (MLO) and (B) craniocaudal (CC) views show surgical clips but no abnormality. (C) Recombined MLO and (D) CC images show an enhancing mass in the medial left breast (arrows). Biopsy revealed invasive lobular carcinoma. Size was 0.2 cm; tumor grade II/III; negative lymph nodes; and estrogen receptor–positive, progesterone receptor–positive, and human epidermal growth factor receptor 2–negative.

Women's Imaging MinnieCast, Episode 13: Partial breast irradiation in the spotlight

By Amerigo Allegretto

Two committee members for ASTRO's PBI guidelines share insights about this breast cancer treatment option.

July 17, 2026

Minnie Cast Thumbnail (15)

Incorrect AI suggestions influence reader performance on mammography

By Amerigo Allegretto

The biggest impact on reader performance stemmed from false-negative AI suggestions.

July 14, 2026

A normal mammogram confirmed by three-year radiologic follow-up illustrates reader-marked regions of interest (ROIs) during (A) unaided (round 1) and (B) artificial intelligence (AI)–assisted (round 2) reading. Each colored dot represents an ROI for recall by a human reader. Readers could mark more than one ROI per case, represented by multiple dots of the same color. During AI-assisted reading, the AI system displayed three visible prompts: two with suspicion of malignancy scores of 35% (left mediolateral oblique [L MLO] and craniocaudal [L CC]) and one with a suspicion of malignancy score of 10% (right craniocaudal [R CC]), shown as polygonal overlays. Without AI, six of 10 readers (60%) marked a false-positive ROI. With AI assistance, this fell to two of 10 (20%). R MLO = right mediolateral oblique.

Breast cancer screening higher among civically engaged women

By Amerigo Allegretto

Women who voted, attended a public meeting, or volunteered are more likely to get their breast cancer screening.

July 14, 2026

Mammogram Calendar 400

Page 1 of 584